低机械指数谐波超声造影对肝癌介入治疗的疗效评估
|
时间:2008-12-10 17:01:26 来源: 作者: |
|
Abstracts Objective. To evaluate the effects of ablation treatment of hepatocellular carcinoma (HCC) by contrast-enhanced harmonic sonography with low mechanical index. Methods. Senty-two patients with HCC were examined using contrast-enhanced harmonic sonography with low mechanical index, route gray scale ultrasonography, color Doppler flow imaging, and contrast-enhanced CT/MR before and after ablation treatment. The number and maximal diameter of the lesions were recorded. Blood sign in the tumor was observed. Results. One hundred and seven lesions were seen by route gray scale ultrasonography and color Doppler flow imaging, and 121 lesions were seen by contrast-enhanced sonography in 72 patients. The diameter of the lesions shown by contrast-enhanced sonography was larger than thatby route gray scale ultrasonography. The accuracy of detecting blood sign in the tuomor by contrast-enhanced sonography was the best. Conclusions. Contrast-enhanced sonogram is a valuable tool for assessing the therapeutic effects of interventional treatment on hepatocellular carcinoma.
KEY WORDS contrast-enhanced sonography; liver tumor; ablation; contrast-enhanced CT/MR; therapeutic effect
目前肝脏恶性肿瘤的首选治疗方法仍是手术切除,但多数肿瘤在发现时已丧失了手术机会,因此肝脏恶性肿瘤的非手术治疗越来越受到人们的重视。目前常用的非手术治疗方法包括肝动脉插管化疗栓塞、经皮瘤内无水酒精注射治疗、射频消融治疗或微波凝固治疗等[1],但以上方法均难以保证在单次治疗后使肿瘤完全坏死,因此其疗效的判断关系到治疗方案的制定及患者的预后。本研究拟探讨低机械指数谐波超声造影在肝癌介入治疗疗效评估中的价值。
资料与方法
一、研究对象
2004年3月至2005年6月共对72例行介入治疗的HCC患者进行了低机械指数超声谐波造影检查,其中男47例,女25例,年龄32~85岁,平均51岁。35例行射频消融治疗(RFA组),13例行微波凝固治疗(MCT组),11例行肝动脉化疗栓塞(TACE组),7例行超声引导经皮穿刺瘤内无水乙醇注射治疗(PEIT组),6例行RFA联合TACE或PEIT(联合治疗组)。
二、仪器与方法
采用GE Logiq 9、Esaote DU8彩色多普勒超声仪,具有低机械指数实时谐波超声造影功能,GE Logiq 9探头发射频率2.0MHz,接受频率4.0MHz;DU 8探头发射频率2.5MHz,接受频率5.0MHz,机械指数0.05~0.08。造影剂为Bracco公司的SonoVue(声诺维)59mg干粉剂,用5ml生理盐水配制成六氟化硫微泡混悬液,振荡混匀后抽2.4 ml经肘部浅静脉弹丸式注入(1ml/s)。RFA组、MCT组和联合治疗组超声造影分别于介入治疗前和热消融治疗结束后10分钟以及术后1月进行;TACE组、PEIT组则分别于治疗前和治疗后1月进行。此后,所有患者每1~3月随访一次,随访时间为1~18月,平均随访9.7月。实时观察病灶内造影剂的灌注情况,包括动脉相、门脉相及延迟相肿瘤内部及周边有无增强,各期均无增强提示肿瘤被完全灭活;肿瘤内或周边动脉相高增强、门脉相或延迟相低增强或无增强则提示肿瘤残留。门脉相、延迟相扫查全肝,了解有无细小病灶或新病灶。所有患者造影前均做常规二维(2D)超声、彩色多普勒血流显像(CDFI)检查,记录病灶数目、大小,观察病灶内血供。术前及术后月行增强CT/MRI检查。
三、统计学处理
采用SPSS10.0统计软件,计量资料做配对t检验,计数资料做组间Χ2检验,以P<0.05为差异有显著性意义。
|
|
|
|